These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 6170849)

  • 1. [Immunogenic properties and specificity of pseudomonas aeruginosa polyvalent vaccine].
    Schiller B; Lysakowska E; Owczarska K
    Med Dosw Mikrobiol; 1981; 33(2):91-6. PubMed ID: 6170849
    [No Abstract]   [Full Text] [Related]  

  • 2. [Immunogenic properties of a polyvalent vaccine against Pseudomonas aeruginosa].
    Serafińska D; Bukowska D; Sokołowska K; Nasiłowski W
    Pol Tyg Lek; 1980 Jul; 35(27):1013-5. PubMed ID: 6775310
    [No Abstract]   [Full Text] [Related]  

  • 3. An acellular vaccine from Pseudomonas aeruginosa: homologous and crossed protection between serogroups according to Habs' classification.
    Berche P; Véron M; Fermanian J; Daoulas-Lebourdelles F; Guégen A
    Ann Microbiol (Paris); 1979; 130(2):179-88. PubMed ID: 90473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pseudomonas aeruginosa. II. Experimental acellular vaccine of an endotoxin and anatoxin type.
    Bĕlohlávek S; Pavlík V; Rencová J; Stránský V; Nováková L; Sourek J; Výmola F
    J Hyg Epidemiol Microbiol Immunol; 1987; 31(3):343-52. PubMed ID: 3119704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Active and passive mouse-protecting capacity of Pseudomonas aeruginosa protein vaccines.
    Joó I; Stanislavsky ES; Zhvanetskaya MI; Mashilova GM; Gladus MA
    Acta Microbiol Acad Sci Hung; 1982; 29(4):267-75. PubMed ID: 6821018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Derivation and experimental evaluation of polyvalent corpuscular vaccine for prevention of infections caused by Pseudomonas aeruginosa. I. Development of polyvalent corpuscular vaccine].
    Moroz AF; Radkevich SA; Antsiferova NG; Brodinova NS
    Zh Mikrobiol Epidemiol Immunobiol; 1981; (8):44-9. PubMed ID: 6171956
    [No Abstract]   [Full Text] [Related]  

  • 7. A new polyvalent pseudomonas vaccine.
    Merle P; Robbel L; Hungerer KD
    Behring Inst Mitt; 1984 Nov; (76):113-20. PubMed ID: 6441560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protective characteristics of the antigen common to Pseudomonas and Vibrio and significance of bacterial endotoxins in protection against selected bacterial infections.
    Sourek J
    Zentralbl Bakteriol Mikrobiol Hyg A; 1985 Jul; 259(4):538-47. PubMed ID: 2413656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pseudomonas aeruginosa preparations for active immunization].
    Nazarchuk LV
    Vrach Delo; 1991 Jul; (7):22-7. PubMed ID: 1771827
    [No Abstract]   [Full Text] [Related]  

  • 10. Application of vaccine technology to prevention of Pseudomonas aeruginosa infections.
    Pier G
    Expert Rev Vaccines; 2005 Oct; 4(5):645-56. PubMed ID: 16221066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conjugate vaccines against Pseudomonas aeruginosa and malaria.
    Cryz SJ; Sadoff JC; Que JU
    Contrib Microbiol Immunol; 1989; 10():166-89. PubMed ID: 2510972
    [No Abstract]   [Full Text] [Related]  

  • 12. [[Vaccine development for P. aeruginosa: based on antigen cloning of clinical vaccines][].
    von Specht BU
    Zentralbl Chir; 1999; 124(4):298-302. PubMed ID: 10355084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mouse-protection experience with monovalent Pseudomonas aeruginosa vaccine.
    Sourek J; Výmola F; Zelenková L
    Zentralbl Bakteriol A; 1980 Mar; 246(3):353-62. PubMed ID: 6775443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mono--and polyvalent Pseudomonas aeruginosa vaccines. Preparation, control and administration.
    Meitert E; Meitert T; Sima F; Savulian C
    Arch Roum Pathol Exp Microbiol; 1982; 41(2):105-14. PubMed ID: 6816188
    [No Abstract]   [Full Text] [Related]  

  • 15. The immunoprophylaxis and immunotherapy of Pseudomonas infections in burns with polyvalent Pseudomonas aeruginosa corpuscular vaccine.
    Ionescu A; Meitert E; Vasiliu S; Meitert T; Milicescu S; Sima F; Savulian C
    Arch Roum Pathol Exp Microbiol; 1979; 38(3-4):317-30. PubMed ID: 122594
    [No Abstract]   [Full Text] [Related]  

  • 16. The epidemiology of Pseudomonas aeruginosa and the development of a polyvalent vaccine.
    Pranter W; Staerk J; Zellner R; Zwisler O
    Prog Immunobiol Stand; 1971; 5():414-8. PubMed ID: 4633968
    [No Abstract]   [Full Text] [Related]  

  • 17. Multivalent DNA vaccine protects mice against pulmonary infection caused by Pseudomonas aeruginosa.
    Saha S; Takeshita F; Sasaki S; Matsuda T; Tanaka T; Tozuka M; Takase K; Matsumoto T; Okuda K; Ishii N; Yamaguchi K; Klinman DM; Xin KQ; Okuda K
    Vaccine; 2006 Sep; 24(37-39):6240-9. PubMed ID: 16806598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pseudomonas aeruginosa: prevention better than cure?
    Mellor JA; Miler JJ
    Dev Biol Stand; 1979; 43():53-9. PubMed ID: 118071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccines against Pseudomonas aeruginosa results and perspectives of investigations (survey).
    Joó I; Stanislavskii ES
    J Hyg Epidemiol Microbiol Immunol; 1982; 26(4):417-27. PubMed ID: 6819316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody responses induced by long-term vaccination with an octovalent conjugate Pseudomonas aeruginosa vaccine in children with cystic fibrosis.
    Zuercher AW; Horn MP; Que JU; Ruedeberg A; Schoeni MH; Schaad UB; Marcus P; Lang AB
    FEMS Immunol Med Microbiol; 2006 Jul; 47(2):302-8. PubMed ID: 16831219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.